Ciprofloxacin (Cipro) for Urinary Tract Infection

  • Generic Name: Ciprofloxacin
  • Trade Names: Cipro, Cipro XR, ProQuin
  • Pharmacologic Category: Fluoroquinolone antibiotic
  • Dosage Forms: Tablets 250 mg, 500 mg, 750 mg
    Microcapsules for oral suspension 250 mg per 5 mL, 500 mg per 5 mL
    Extended-release tablets 500 mg, 1000 mg

Fluoroquinolone antibiotic ciprofloxacin (Cipro) is widely used to treat Urinary Tract Infections (UTIs) because it reaches high urinary concentrations, has an excellent activity against most uropathogens, and is available in oral and intravenous formulations.

Ciprofloxacin dosage for UTI

Children 1–17 years of age:

Complicated UTIs and pyelonephritis: 10-20 mg/kg (up to 750 mg) every 12 hours for 10-21 days.

Adults:

Cystitis (bladder indection): 250 mg every 12 hours for 3 days.
Cipro XR: 500 mg once daily for 3 days, preferably given with the evening meal.

Mild to moderate UTIs:
The standard dose is 250 mg every 12 hours for 7-14 days.

Complicated UTIs, pyelonephritis: 500 mg every 12 hours for 7-14 days.
Cipro XR: 1 g once daily every for 7–14 days.


How long before ciprofloxacin works on UTI?

Ciprofloxacin usually works fast. You may begin to feel much better within 24 hours. The symptoms are usually gone by day three. Mild symptoms may persist for up to 5-7 days.

The eXtRa study [2] found that more than a third of the women taking Cipro XR (ciprofloxacin extended-release) for the treatment of uncomplicated urinary tract infections get significant improvement within just 3 hours of taking the antibiotic and half of the women reported symptom improvement within 6 hours. Additionally, 87% reported significant symptom improvement and 22% reported complete relief within 24 hours.

Does ciprofloxacin always cure UTI?

No. Ciprofloxacin may fail to cure urinary infection caused by resistant bacteria. Research indicates emerging ciprofloxacin resistance among bacteria causing urinary tract infections. UTI cases caused by E. coli resistant to ciprofloxacin account for about 17% [1].

See also:

Sources & References:

  • 1. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012 Apr;56(4):2181-3.
  • 2. Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections.


Copyright 2013 HealthAssist.net. All rights reserved.
Products mentioned are trademarks of their respective companies.
All information is for educational purposes only.
For medical advice and diagnoses consult your doctor.